Disparity Analysis of Clinicopathologic Hallmarks between Transformed DLBCL and Primary DLBCL

Clin Lab. 2022 Jul 1;68(7). doi: 10.7754/Clin.Lab.2021.211028.

Abstract

Background: A variety of indolent lymphomas, particularly marginal zone lymphoma (MZL) and follicular lymphoma (FL) can be histologically transformed to diffuse large B-cell lymphoma (DLBCL). Little is known about the disparity of clinicopathologic characteristics between transformed DLBCL (tDLBCL) and primary DLBCL (pDLBCL).

Methods: This retrospective study analyzed the clinicopathological hallmarks of 10 tDLBCL (7 MZL and 3 FL) and 40 pDLBCL from the Affiliated Hospital of Xuzhou Medical University.

Results: Patients of tDLBCL had a higher ECOG score, more B-symptoms, and lower serum albumin level than those in pDLBCL (60.0% vs. 7.50%, 40.0% vs. 10.0%, and 90.0% vs. 10.0%, respectively, p < 0.01). Pathologically, tDLBCL had more c-Myc and BCL-2 dual-expression than that in pDLBCL (60.0% vs. 25.0%, p < 0.01). The positive rate of CD5 expression and the proportion of high Ki-67 score in tDLBCL were higher than those in pDLBCL (50.0% vs. 7.5%, 50.0% vs. 32.5%, respectively, p < 0.01). The median overall survival and progression-free survival were 14 months and 11 months in tDLBCL, 35 months and 28 months in pDLBCL (p < 0.05 and p < 0.001).

Conclusions: Our results demonstrate that tDLBCL manifested aggressive clinical course and pathological features of Myc/BCL-2 expression, CD5 expression, and high Ki-67 score.

MeSH terms

  • Humans
  • Ki-67 Antigen
  • Lymphoma, Follicular*
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2
  • Retrospective Studies

Substances

  • Ki-67 Antigen
  • Proto-Oncogene Proteins c-bcl-2